Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Centogene N.V. (CNTG)

Centogene N.V. (CNTG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,801
  • Shares Outstanding, K 27,080
  • Annual Sales, $ 52,700 K
  • Annual Income, $ -38,580 K
  • EBIT $ -63 M
  • EBITDA $ -55 M
  • 60-Month Beta -0.67
  • Price/Sales 0.19
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.67
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/21/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2511 +29.43%
on 07/31/24
0.5501 -40.92%
on 07/16/24
-0.1170 (-26.47%)
since 07/05/24
3-Month
0.2511 +29.43%
on 07/31/24
0.5501 -40.92%
on 07/16/24
-0.1250 (-27.78%)
since 05/07/24
52-Week
0.2511 +29.43%
on 07/31/24
1.5300 -78.76%
on 10/31/23
-0.6750 (-67.50%)
since 08/07/23

Most Recent Stories

More News
Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public...

CNTG : 0.3250 (-6.23%)
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG),...

TWST : 42.05 (+1.15%)
CNTG : 0.3250 (-6.23%)
Dammam Valley and Arcensus GmbH to establish Saudi-German Genomic Center in Riyadh

DAMMAM, SAUDI ARABIA, Sep 8, 2022 - (ACN Newswire) - Dammam Valley, in partnership with other investment partners, and Arcensus GmbH announce the establishment of a high-throughput Saudi-German Genomic...

CNTG : 0.3250 (-6.23%)
Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics

ROSTOCK, Germany & DAMMAM, KSA, Sep 5, 2022 - (ACN Newswire) - Dammam Valley in partnership with other investment partners, announce to acquire a majority stake in Arcensus GmbH/Germany. Arcensus, founded...

CNTG : 0.3250 (-6.23%)
CENTOGENE Reports First Quarter 2022 Financial Results

On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022Positioning Pharma and...

CNTG : 0.3250 (-6.23%)
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...

CNTG : 0.3250 (-6.23%)
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...

CNTG : 0.3250 (-6.23%)
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...

CNTG : 0.3250 (-6.23%)
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...

CNTG : 0.3250 (-6.23%)
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18...

CNTG : 0.3250 (-6.23%)
AGIO : 44.83 (-0.09%)

Business Summary

Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company's goal is to bring rationality to treatment decisions and to accelerate the development...

See More

Key Turning Points

3rd Resistance Point 0.5050
2nd Resistance Point 0.4670
1st Resistance Point 0.3960
Last Price 0.3250
1st Support Level 0.2870
2nd Support Level 0.2490
3rd Support Level 0.1780

See More

52-Week High 1.5300
Fibonacci 61.8% 1.0415
Fibonacci 50% 0.8906
Fibonacci 38.2% 0.7396
Last Price 0.3250
52-Week Low 0.2511

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar